Trulance® Safety Adults with CIC or IBS-C. See ISI at the bottom of every page.
Trulance Overview CIC Indication IBS-C Indication Patient Support HCP Resources Investors
Contact HCP Portal
Home/Products

Product portfolio

Focused therapies for gastrointestinal health

TRULANCE® (plecanatide) for adult patients with CIC and IBS-C, plus advancing pipeline candidates built on our GC-C agonist platform.

Trulance overview See pipeline

Portfolio snapshot

Approved therapy and late-stage candidates

TRULANCE® (plecanatide)

GC-C agonist indicated for treatment of adults with chronic idiopathic constipation (CIC) and adults with irritable bowel syndrome with constipation (IBS-C).

  • Indications: CIC and IBS-C in adults
  • Most common adverse reaction: diarrhea
  • Contraindicated in patients under 6 years of age or with suspected/known mechanical GI obstruction
CIC details IBS-C details

Dolcanatide

Investigational GC-C agonist in development for ulcerative colitis, reflecting Synergy’s ongoing investment in GI innovation.

Pipeline candidate overview →
Laboratory research

Indication pathways

Tailored resources by condition

  • Condition education pages for CIC and IBS-C to support patient discussions
  • HCP-focused resources for dosing guidance and ISI review
  • Access and reimbursement information aligned to each indication
Disease education HCP resources →
Questions on our therapies? Contact Synergy at +1 (276) 248-2886 or info@synergycures.com. For emergencies, patients should contact their healthcare provider immediately.